Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Equity Average (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Equity Average for 5 consecutive years, with -$1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 105.24% to -$1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.4 million, a 105.24% decrease, with the full-year FY2024 number at $50.5 million, down 40.64% from a year prior.
  • Equity Average was -$1.4 million for Q3 2025 at Lyra Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $99.7 million in Q3 2022 to a low of -$1.4 million in Q3 2025.
  • A 5-year average of $53.3 million and a median of $58.4 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 155.06% in 2023, then plummeted 105.24% in 2025.
  • Lyra Therapeutics' Equity Average stood at $40.8 million in 2021, then surged by 113.46% to $87.0 million in 2022, then fell by 0.18% to $86.8 million in 2023, then crashed by 81.45% to $16.1 million in 2024, then plummeted by 108.4% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Equity Average are -$1.4 million (Q3 2025), $2.7 million (Q2 2025), and $7.7 million (Q1 2025).